ALK and non-small cell lung carcinoma: A phase 2 trial known as eX-alt3 enrolled 290 patients with ALK-positive NSCLC patients to compare ensartinib treatment against crizotinib through risk reduction analysis that found PFS improving from 13 to 26 months (HR 0.51, 95% CI 0.35–0.72) [22].